DDInter1331 DDInter1676
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Olodaterol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norfloxacin
Olodaterol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lithium carbonate
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Macimorelin
Olodaterol {u} may lead to a major life threatening interaction when taken with {v} Cocaine
Olodaterol may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin
Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Olodaterol may lead to a major life threatening interaction when taken with Macimorelin
Olodaterol may lead to a major life threatening interaction when taken with Cocaine